Incontinence may be defined as the involuntary loss of bladder or bowel
control. In the United States (U.S.), urinary incontinence (UI) afflicts an
estimated 50 million people. According to the National Association for
Continence (NAFC), approximately 75% to 80% of the UI populations are women,
with 9 million to 13 million suffering severe symptoms.
Although UI is an extremely common problem, and has a significant impact on
quality of life, the vast majority of those who experience the condition do
not undergo treatment, in part due to cost, embarrassment, or fear of risky
surgical procedures. There is therefore a very strong demand for less costly,
less invasive and more tolerable, discreet, nonsurgical UI therapies.
While current economic conditions and other factors continue to restrain
market growth, the market for minimally invasive UI therapy systems is
expected to exhibit relatively strong growth over the next 5 years. Valued at
more than $190 million in 2010, the U.S. Minimally Invasive Urinary
Incontinence Therapy Systems market is expected to increase at a healthy
compound annual rate of 2.7%, with sales reaching more than $220 million in
2015. The market is expected to benefit not only from strong demand but from
highly positive demographic trends, including a large, growing UI population
and limited options for truly effective therapeutic alternatives.
This dynamic report from Medtech Insight includes analyses of products,
markets, competitors, and emerging technology and opportunities. Covered
topics in this report include injectable urethral bulking agents; urethral
sling systems; implantable sacral nerve neurostimulators; nonsurgical
office-based neuromodulation/percutaneous tibial nerve stimulation; and other